Glucagon therapeutics: Dawn of a new era for diabetes care

Jaime A. Davidson, William L Holland, Michael G Roth, May-Yun Wang, Young H Lee, Xinxin Yu, Sara K. McCorkle, Philipp E Scherer, Roger H Unger

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Although insulin monotherapy prevents death from ketoacidosis, it does not prevent either the hyperglycemic surges or the hypoglycemic plunges of glucose levels that plague the majority of patients with type 1 diabetes. However, significant improvements have occurred with the combination of continuous insulin delivery matched by continuous glucose monitoring, but the technology is not available for all patients, requires extensive education, is expensive and moreover, while much better than standard care, it almost never reduces haemoglobin A1c (HbA1c) to below 6%. This may indicate that an improved diabetes therapy involving antagonism of glucagon action will for the first time control glucose levels to normal and eradicate the long-term complications of diabetes. Although one can never predict that results in animals will be reproduced in humans, the available evidence suggests that patients with type 1 and type 2 diabetes may expect far superior control of the metabolic abnormalities without the need for significant monitoring of glucose, a very important but expensive part of any insulin regimen.

Original languageEnglish (US)
Pages (from-to)660-665
Number of pages6
JournalDiabetes/Metabolism Research and Reviews
Volume32
Issue number7
DOIs
StatePublished - Oct 1 2016

Fingerprint

Glucagon
Glucose
Insulin
Type 1 Diabetes Mellitus
Ketosis
Plague
Diabetes Complications
Therapeutics
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Hemoglobins
Technology
Education

Keywords

  • diabetes
  • glucagon
  • glucagon receptor
  • haemoglobin A
  • insulin
  • treatment of diabetes
  • type 1 and type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Glucagon therapeutics : Dawn of a new era for diabetes care. / Davidson, Jaime A.; Holland, William L; Roth, Michael G; Wang, May-Yun; Lee, Young H; Yu, Xinxin; McCorkle, Sara K.; Scherer, Philipp E; Unger, Roger H.

In: Diabetes/Metabolism Research and Reviews, Vol. 32, No. 7, 01.10.2016, p. 660-665.

Research output: Contribution to journalReview article

@article{2fd1e585a82a4956961804481349ea38,
title = "Glucagon therapeutics: Dawn of a new era for diabetes care",
abstract = "Although insulin monotherapy prevents death from ketoacidosis, it does not prevent either the hyperglycemic surges or the hypoglycemic plunges of glucose levels that plague the majority of patients with type 1 diabetes. However, significant improvements have occurred with the combination of continuous insulin delivery matched by continuous glucose monitoring, but the technology is not available for all patients, requires extensive education, is expensive and moreover, while much better than standard care, it almost never reduces haemoglobin A1c (HbA1c) to below 6{\%}. This may indicate that an improved diabetes therapy involving antagonism of glucagon action will for the first time control glucose levels to normal and eradicate the long-term complications of diabetes. Although one can never predict that results in animals will be reproduced in humans, the available evidence suggests that patients with type 1 and type 2 diabetes may expect far superior control of the metabolic abnormalities without the need for significant monitoring of glucose, a very important but expensive part of any insulin regimen.",
keywords = "diabetes, glucagon, glucagon receptor, haemoglobin A, insulin, treatment of diabetes, type 1 and type 2 diabetes",
author = "Davidson, {Jaime A.} and Holland, {William L} and Roth, {Michael G} and May-Yun Wang and Lee, {Young H} and Xinxin Yu and McCorkle, {Sara K.} and Scherer, {Philipp E} and Unger, {Roger H}",
year = "2016",
month = "10",
day = "1",
doi = "10.1002/dmrr.2773",
language = "English (US)",
volume = "32",
pages = "660--665",
journal = "Diabetes/Metabolism Research and Reviews",
issn = "1520-7552",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Glucagon therapeutics

T2 - Dawn of a new era for diabetes care

AU - Davidson, Jaime A.

AU - Holland, William L

AU - Roth, Michael G

AU - Wang, May-Yun

AU - Lee, Young H

AU - Yu, Xinxin

AU - McCorkle, Sara K.

AU - Scherer, Philipp E

AU - Unger, Roger H

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Although insulin monotherapy prevents death from ketoacidosis, it does not prevent either the hyperglycemic surges or the hypoglycemic plunges of glucose levels that plague the majority of patients with type 1 diabetes. However, significant improvements have occurred with the combination of continuous insulin delivery matched by continuous glucose monitoring, but the technology is not available for all patients, requires extensive education, is expensive and moreover, while much better than standard care, it almost never reduces haemoglobin A1c (HbA1c) to below 6%. This may indicate that an improved diabetes therapy involving antagonism of glucagon action will for the first time control glucose levels to normal and eradicate the long-term complications of diabetes. Although one can never predict that results in animals will be reproduced in humans, the available evidence suggests that patients with type 1 and type 2 diabetes may expect far superior control of the metabolic abnormalities without the need for significant monitoring of glucose, a very important but expensive part of any insulin regimen.

AB - Although insulin monotherapy prevents death from ketoacidosis, it does not prevent either the hyperglycemic surges or the hypoglycemic plunges of glucose levels that plague the majority of patients with type 1 diabetes. However, significant improvements have occurred with the combination of continuous insulin delivery matched by continuous glucose monitoring, but the technology is not available for all patients, requires extensive education, is expensive and moreover, while much better than standard care, it almost never reduces haemoglobin A1c (HbA1c) to below 6%. This may indicate that an improved diabetes therapy involving antagonism of glucagon action will for the first time control glucose levels to normal and eradicate the long-term complications of diabetes. Although one can never predict that results in animals will be reproduced in humans, the available evidence suggests that patients with type 1 and type 2 diabetes may expect far superior control of the metabolic abnormalities without the need for significant monitoring of glucose, a very important but expensive part of any insulin regimen.

KW - diabetes

KW - glucagon

KW - glucagon receptor

KW - haemoglobin A

KW - insulin

KW - treatment of diabetes

KW - type 1 and type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84989851150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989851150&partnerID=8YFLogxK

U2 - 10.1002/dmrr.2773

DO - 10.1002/dmrr.2773

M3 - Review article

C2 - 26729301

AN - SCOPUS:84989851150

VL - 32

SP - 660

EP - 665

JO - Diabetes/Metabolism Research and Reviews

JF - Diabetes/Metabolism Research and Reviews

SN - 1520-7552

IS - 7

ER -